113 related articles for article (PubMed ID: 9726023)
1. Ras p21 protein levels in human plasma from patients with chronic obstructive pulmonary disease (COPD) compared with lung cancer patients and healthy controls.
Anderson D; Hughes JA; Cebulska-Wasilewska A; Nizankowska E; Graca B
Mutat Res; 1998 Jul; 403(1-2):229-35. PubMed ID: 9726023
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic damage and ras p21 oncoprotein levels from patients with chronic obstructive pulmonary disease (COPD), untreated lung cancer and healthy controls.
Cebulska-Wasilewska A; Wierzewska A; Nizankowska E; Graca B; Hughes JA; Anderson D
Mutat Res; 1999 Dec; 431(1):123-31. PubMed ID: 10656491
[TBL] [Abstract][Full Text] [Related]
3. ras oncoproteins in human plasma from lung cancer patients and healthy controls.
Anderson D; Hughes JA; Cebulska-Wasilewska A; Nizankowska E; Graca B
Mutat Res; 1996 Jan; 349(1):121-6. PubMed ID: 8569784
[TBL] [Abstract][Full Text] [Related]
4. Expression of ras (p21) protein in plasma from exposed workers and from patients with lung disease.
Anderson D
Int J Hyg Environ Health; 2001 Oct; 204(1):55-60. PubMed ID: 11725347
[TBL] [Abstract][Full Text] [Related]
5. Serum ras (p21) as a marker for occupationally derived lung cancer?
Schneider J; Presek P; Braun A; Löffler S; Woitowitz HJ
Clin Chem Lab Med; 2000 Apr; 38(4):301-5. PubMed ID: 10928648
[TBL] [Abstract][Full Text] [Related]
6. Association between the ras p21 oncoprotein in blood samples and breast cancer.
Rundle A; Tang D; Brandt-Rauf P; Zhou J; Kelly A; Schnabel F; Perera FP
Cancer Lett; 2002 Nov; 185(1):71-8. PubMed ID: 12142081
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
Banys-Paluchowski M; Fehm T; Janni W; Aktas B; Fasching PA; Kasimir-Bauer S; Milde-Langosch K; Pantel K; Rack B; Riethdorf S; Solomayer EF; Witzel I; Müller V
BMC Cancer; 2018 May; 18(1):541. PubMed ID: 29739347
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting various biomarkers in untreated lung cancer patients and healthy donors.
Anderson D; Hughes JA; Nizankowska E; Graca B; Cebulska-Wasilewska A; Wierzewska A; Kasper E
Environ Mol Mutagen; 1997; 30(2):205-16. PubMed ID: 9329645
[TBL] [Abstract][Full Text] [Related]
9. High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer.
Yakubovskaya MS; Spiegelman V; Luo FC; Malaev S; Salnev A; Zborovskaya I; Gasparyan A; Polotsky B; Machaladze Z; Trachtenberg AC
Int J Cancer; 1995 Dec; 63(6):810-4. PubMed ID: 8847139
[TBL] [Abstract][Full Text] [Related]
10. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model.
Moghaddam SJ; Li H; Cho SN; Dishop MK; Wistuba II; Ji L; Kurie JM; Dickey BF; Demayo FJ
Am J Respir Cell Mol Biol; 2009 Apr; 40(4):443-53. PubMed ID: 18927348
[TBL] [Abstract][Full Text] [Related]
11. Association between the p21 codon 31 A1 (arg) allele and lung cancer.
Själander A; Birgander R; Rannug A; Alexandrie AK; Tornling G; Beckman G
Hum Hered; 1996; 46(4):221-5. PubMed ID: 8807325
[TBL] [Abstract][Full Text] [Related]
12. Plasma beta-endorphin concentrations are increased in chronic obstructive pulmonary disease patients.
Hjalmarsen A; Viitanen M; Jenssen T; Jorde R; Johansen O
Scand J Clin Lab Invest; 2000 Oct; 60(6):501-6. PubMed ID: 11129066
[TBL] [Abstract][Full Text] [Related]
13. Is there any relationship between plasma antioxidant capacity and lung function in smokers and in patients with chronic obstructive pulmonary disease?
Rahman I; Swarska E; Henry M; Stolk J; MacNee W
Thorax; 2000 Mar; 55(3):189-93. PubMed ID: 10679536
[TBL] [Abstract][Full Text] [Related]
14. Decrease in K-ras p21 and increase in Raf1 and activated Erk 1 and 2 in murine lung tumors initiated by N-nitrosodimethylamine and promoted by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Ramakrishna G; Perella C; Birely L; Diwan BA; Fornwald LW; Anderson LM
Toxicol Appl Pharmacol; 2002 Feb; 179(1):21-34. PubMed ID: 11884234
[TBL] [Abstract][Full Text] [Related]
15. Ras p21 onco-protein in the sera of mice carrying an experimentally induced tumor and in human cancer patients.
Kakkanas A; Spandidos DA
In Vivo; 1990; 4(2):115-20. PubMed ID: 2129802
[TBL] [Abstract][Full Text] [Related]
16. COPD-related adenocarcinoma presents low aggressiveness morphological and molecular features compared to smoker tumours.
Schiavon M; Marulli G; Nannini N; Pasello G; Lunardi F; Balestro E; Perissinotto E; Rebusso A; Saetta M; Rea F; Calabrese F
Lung Cancer; 2014 Dec; 86(3):311-7. PubMed ID: 25454198
[TBL] [Abstract][Full Text] [Related]
17. Zinc oxide nanoparticles affect the expression of p53, Ras p21 and JNKs: an ex vivo/in vitro exposure study in respiratory disease patients.
Kumar A; Najafzadeh M; Jacob BK; Dhawan A; Anderson D
Mutagenesis; 2015 Mar; 30(2):237-45. PubMed ID: 25381309
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease.
Doubková M; Karpíšek M; Mazoch J; Skřičková J; Doubek M
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Oct; 33(3):224-234. PubMed ID: 27758987
[TBL] [Abstract][Full Text] [Related]
19. High-throughput qRT-PCR validation of blood microRNAs in non-small cell lung cancer.
Leidinger P; Brefort T; Backes C; Krapp M; Galata V; Beier M; Kohlhaas J; Huwer H; Meese E; Keller A
Oncotarget; 2016 Jan; 7(4):4611-23. PubMed ID: 26672767
[TBL] [Abstract][Full Text] [Related]
20. Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.
Dowler Nygaard A; Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Oncol Rep; 2014 Feb; 31(2):969-74. PubMed ID: 24316734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
